Le Lézard1h
Boehringer Ingelheim Expands Research and Development in Athens, Georgia
Boehringer Ingelheim announced the grand opening of its newly expanded research and development facility in Athens, Georgia. As the largest animal health company in Georgia, this Boehringer ...
Zawya8d
More than 300 regional experts gather in Cairo for Boehringer Ingelheim’s Forums
Hosted by Boehringer Ingelheim, the ‘CRM Summit’, an expert engagement forum, and the ‘IMETA CRM Discussions for EXperts ...
Pharmabiz13d
Boehringer Ingelheim, Circle Pharma ink research collaboration to develop a novel precision cancer treatment
Boehringer Ingelheim, Circle Pharma ink research collaboration to develop a novel precision cancer treatment: Ingelheim, Germany Friday, October 11, 2024, 12:00 Hrs [IST] Boehring ...
Business Wire15d
Boehringer Ingelheim and Circle Pharma Announce New Research Collaboration to Develop a Novel Precision Cancer Treatment
--(BUSINESS WIRE)--Boehringer Ingelheim and Circle Pharma (Circle ... Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry’s top investors ...
Financial Post29d
Boehringer Ingelheim expands cancer research at its Vienna site
around 25% of Human Pharma net sales, ranking Boehringer Ingelheim among the top R&D investors in the industry. “Our goal is to create more health for humans and animals,” says Paola Casarosa, Head of ...
Boehringer Ingelheim: Boehringer receives U.S. FDA Breakthrough Therapy designation and initiates two phase III trials in MASH for survodutide
The U.S. FDA Breakthrough Therapy designation is for the treatment of adults with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) and moderate or advanced fibrosis, based on surv ...